Renaissance Technologies LLC Has $48.30 Million Position in Edwards Lifesciences Co. (NYSE:EW)

Renaissance Technologies LLC decreased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 46.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 652,493 shares of the medical research company's stock after selling 569,207 shares during the quarter. Renaissance Technologies LLC owned approximately 0.11% of Edwards Lifesciences worth $48,304,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC grew its holdings in shares of Edwards Lifesciences by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company's stock valued at $889,050,000 after acquiring an additional 284,918 shares in the last quarter. Coldstream Capital Management Inc. boosted its position in Edwards Lifesciences by 14.9% in the 3rd quarter. Coldstream Capital Management Inc. now owns 9,382 shares of the medical research company's stock valued at $620,000 after buying an additional 1,219 shares during the last quarter. Neo Ivy Capital Management bought a new position in Edwards Lifesciences during the 3rd quarter worth approximately $726,000. Toronto Dominion Bank raised its stake in shares of Edwards Lifesciences by 1.4% in the 3rd quarter. Toronto Dominion Bank now owns 300,280 shares of the medical research company's stock valued at $19,815,000 after purchasing an additional 4,008 shares during the period. Finally, Teachers Retirement System of The State of Kentucky increased its holdings in Edwards Lifesciences by 43.5% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 138,755 shares of the medical research company's stock worth $9,156,000 after buying an additional 42,059 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

EW has been the subject of a number of research analyst reports. Truist Financial lowered their price target on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a report on Friday, April 11th. Stifel Nicolaus raised Edwards Lifesciences from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Evercore ISI dropped their price objective on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a report on Wednesday, February 12th. Royal Bank of Canada reiterated an "outperform" rating and set a $85.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Finally, Canaccord Genuity Group lifted their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $78.55.

Insiders Place Their Bets

In related news, VP Daniel J. Lippis sold 500 shares of the company's stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. This represents a 2.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the company's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at $3,189,770.56. The trade was a 16.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 72,353 shares of company stock worth $5,197,442 in the last three months. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Price Performance

EW stock traded up $0.75 during mid-day trading on Wednesday, hitting $71.51. 1,000,106 shares of the stock were exchanged, compared to its average volume of 4,618,560. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The business has a fifty day moving average price of $71.27 and a 200 day moving average price of $70.76. The stock has a market capitalization of $42.04 billion, a price-to-earnings ratio of 10.26, a PEG ratio of 4.82 and a beta of 1.15.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.